Mobile

A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the...

Update Il y a 4 ans
Reference: EUCTR2014-000132-41

A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the efficacy of rituximab-Pfizer to rituximab-EU when administered as a first-line treatment to patients with CD20-positive, low tumor burden follicular lymphoma (LTB-FL). Comparar la eficacia de rituximab-Pfizer con rituximab-UE al administrarlo como tratamiento de primera línea a pacientes con linfoma folicular y baja carga tumoral (LF-BCT) CD20 positivo.

Inclusion criteria

  • low tumor burden follicular lymphoma,linfoma folicular de baja carga tumoral

Links